No Data
No Data
Zhongtai Securities: Steady performance under the influence of policies and fundamentals, grasping investment opportunities driven by medical device innovation+ inflection points
The medical device industry continues to grow rapidly. It is optimistic about importation substitution and global development driven by innovation. Volume procurement policies will continue to be implemented, medical anti-corruption is expected to ease, and sector valuations are expected to gradually recover.
Runmed-B (02297.HK) was increased by 300,000 shares by Chairman and Executive Director Huo Yunfei
Glonghui, May 3, 丨 According to the latest equity disclosure data of the Stock Exchange, on April 29, 2024, Runmed-B (02297.HK) was increased by 300,000 shares by Chairman of the Board of Directors and Executive Director Huo Yunfei at an average price of HK$0.14 per share on the market, involving approximately HK$42,000. After the increase in holdings, Huo Yunfei's latest shareholding was 218,733,000 shares, and the shareholding ratio increased from 18.70% to 18.73%.
潤邁德-B:二零二三年年度報告
Rainmed-B (02297) announces 2023 annual results. Shareholders' share loss of 116 million yuan narrowed by 91.4% year-on-year
Rainmed-B (02297) announced its results for the year ended December 31, 2023, and the group achieved acceptance during the period...
RAINMED-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Rainmed-B (02297.HK) plans to hold a board meeting on March 28 to consider and approve annual results
Glonghui, March 8 | Runmed-B (02297.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to consider and approve the annual results and publication of the Company and its subsidiaries for the year ended 31 December 2023, and to consider the payment of a final dividend (if any), and to deal with other matters.
No Data